Scientific Program

Conference Series Ltd invites all the participants across the globe to attend Global Summit on Heart Diseases and Therapeutics Chicago, Illinois, USA.

Day 1 :

Conference Series Heart Diseases 2016 International Conference Keynote Speaker Yoshiaki Omura photo
Biography:

.

Abstract:

.

Keynote Forum

Yoshiaki Omura

Adjunct Professor of Family & Community Medicine, New York Medical College, USA

Keynote: Non-invasive quick diagnosis of cardiovascular diseases from visible and invisible changes on eyebrows & upper lip and their safe & effective treatment

Time : 10:25-11:10

Conference Series Heart Diseases 2016 International Conference Keynote Speaker Yoshiaki Omura photo
Biography:

Yoshiaki Omura received both Oncology Residency Training and a Doctor of Science Degree through research on Pharmaco-Electro Physiology of Single Cardiac Cells in vivo and in vitro from Columbia University. He has published over 250 articles and 7 books. He is Executive Editor of Integrative Oncology & Editorial Board Member of Journal of Clinical Trials in Cardiology, etc. Using his new diagnostic method, which received U.S. patent, he can non-invasively and rapidly measure many neurotransmitters, other chemicals, asbestos, viruses, and bacteria. He developed non-invasive quick diagnostic methods of malignancies, as well as a method of evaluating the effects of any treatment.

Abstract:

The method of Electro-magnetic Field (EMF) Resonance phenomenon between 2 identical molecules of identical weight was originally developed at Pupin Laboratory of Graduate Experimental Physics division of Columbia University. Using this method, we can non-invasively & rapidly detect any molecules that exist inside of the body including the brain. Using this method, which received US patent in 1993, we were able to map most of the organ’s representation areas on the surface of the Face, Tongue, Hands, & Feet. When there is any abnormality for a specific internal organ, we found there will always be invisible or visible abnormalities that can be detected on the organ representation areas of the abnormal organ. About 7 years ago, we were able to map the organ representation area of the eyebrows. In the eyebrows, every organ is represented. The part of the eyebrows nearest to the nose represents the cardiovascular (CV) system. When there is an abnormality of the CV system, the hair in the eyebrow closest to the nose becomes whiter. Then, when the problem progresses, the white hair begins to disappear. Therefore, just by seeing the eyebrows, we can detect visible abnormalities on the CV representation areas of the eyebrow. When the hair at the eyebrows does not exist, there is almost always an abnormal response in the area where the hair is missing, For example, in the area where there is no hair of CV system representation area, Cardiac Troponin I is significantly increased. If the patient has atrial fibrillation, in the CV representation area, particularly corresponding to SA node and atrium area, there is a significant EMF resonance with monoclonal antibody of Borrelia Burgdorferi (B.B.) spirochaete and a corresponding significant increase of ANP in the infected part of the heart at corresponding part of ECGs such as SA node area & P-wave. On the face, among several CV representation areas, there is another important CV representation area existing at the left upper lip near the center of the mouth.

Keynote Forum

Louis Samuels

Thomas Jefferson University School of Medicine, USA

Keynote: Beating heart pump-assisted direct coronary artery bypass (PAD-CAB): The best of both worlds

Time : 11:30-12:15

Conference Series Heart Diseases 2016 International Conference Keynote Speaker Louis Samuels photo
Biography:

Louis Samuels graduated Medical School from Hahnemann University (Philadelphia, PA) in 1987 and completed his Cardiothoracic Surgical training in 1995. He joined the faculty of Drexel University as the Surgical Director of Cardiac Transplantation. In 2001, Dr. Samuels and his team implanted the world’s 5th totally implantable electric artificial heart (AbioCor™). In 2003, he joined the Main Line Health System as the Surgical Director of Heart Failure. In addition to cardiac transplantation and LVAD implantation, Dr. Samuels performs CABG and Valvular surgery. In 2012, Dr. Samuels became Professor of Surgery at Thomas Jefferson University School of Medicine. Dr. Samuels has authored over 100 peer reviewed manuscripts and serves as a reviewer for the Annals of Thoracic Surgery. In addition to participating in several clinical trials related to mechanical circulatory support, he continues to serve as a consultant and medical advisor to new technologies currently in trial.

Abstract:

Coronary Artery Bypass Grafting (CABG) is the most common cardiac surgery operation in adults.  The clinical history of this procedure can be dated back to the 1960s when various surgeons began to consider coronary revascularization with a graft.  At that time, the heart-lung machine was still a device with considerable challenges separate from the technical aspects of the operation itself.  As such, the first bypass procedures were done Off-Pump on the beating heart, typically to the RCA only.  With improvements in technology, coronary bypass grafting expanded to multi-vessel procedures utilizing cardio-pulmonary bypass, aortic cross-clamping, and cardioplegic arrest.  This traditional technique afforded a near-perfect environment in which hemodynamic stability could be maintained while grafting the coronaries in a motionless field.  The traditional CABG was, and remains, the standard by which all other techniques of coronary revascularization is measured.  And the results, by the way, are excellent.

In the past two decades, alternatives to the traditional CABG have been proposed and tested by numerous surgeons—an attempt to minimize or eliminate the sequellae associated with the body’s exposure to the heart-lung machine.    One area of investigation was considered and implemented:  OFF-PUMP CABG (OP-CAB).  The idea behind the OP-CAB was to determine if the CABG operation can be conducted on the beating heart without the support of the heart-lung machine.  Special industry-sponsored devices (i.e. stabilizers) were developed to help accomplish this goal.  Many manuscripts were published describing the techniques and outcomes of the OP-CAB procedure—some supporting its use and others showing no advantage over the traditional CABG.  Often absent from these manuscripts are the “intangibles”—the stress on the surgeon and anesthesiologist while trying to perform the procedure; the difficulty in training residents and fellows to do the procedure; the “near misses” when events during the procedure (e.g. arrhythmia, hypotension, ST segment changes) force an emergency conversion to a traditional CABG; and the suggestion that some territories were left ungrafted for “technical reasons”.

In an effort to determine if a “hybrid” approach could afford the benefits of a beating heart technique utilizing the heat-lung machine, but without aortic cross-clamping and cardioplegic arrest, the pump-assisted CABG (PAD-CAB) was examined. 

The purpose of this talk is to describe my experience with the PAD-CAB procedure from 2005 through 2016.  During this time frame, more than 300 PAD-CAB cases were performed, representing 37% of the overall number of CABG cases (No. 834).  Since 2013, the PAD-CAB approach represented 84% of the CABG cases; and since 2015, the PAD-CAB technique was utilized in 96% of the cases.  Overall, the hospital and 30-d mortality for all PAD-CAB procedures was 0.65%, with only 1 death (0.35%) in the last 288 procedures.  The majority of cases were men (76%), the average age was 67 years (range: 38 – 91 years), and the average number of grafts was 3.2 (range 1 – 5). Thirty-nine cases (12.7%) were emergent.  

In summary, the PAD-CAB procedure is safe and effective and should be considered as an alternative to the traditional CABG.